Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice
Zhongbing Liu, Jinwei Li, Juan Li, Juan Huang, Famin Ke, Qiaona Qi, Xing Jiang, Zhirong ZhongLuzhou Medical College, Luzhou, Sichuan, People's Republic of ChinaBackground: It has been reported that the tumor suppressor gene, PTEN, which is inactivated in many malignant tumors, plays an i...
Guardado en:
Autores principales: | Liu Z, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3469d69deb6346209489282fcffe6721 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FBXO22 degrades nuclear PTEN to promote tumorigenesis
por: Meng-Kai Ge, et al.
Publicado: (2020) -
Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer
por: Deng L, et al.
Publicado: (2020) -
Preclinical studies of N3-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H22-bearing mice
por: Zhang J, et al.
Publicado: (2014) -
NLK is a novel therapeutic target for PTEN deficient tumour cells.
por: Ana M Mendes-Pereira, et al.
Publicado: (2012) -
GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers
por: Xu WW, et al.
Publicado: (2017)